TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2895594

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 36
Study: 31906607

Group type: EXPERIMENTAL
Intervention: Median approach (Group M)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Paramedian approach (Group P)
Number of subjects: 100
Study: 29431632

Group type: EXPERIMENTAL
Intervention: Elimination of non-PV triggers (group A, n=250)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Stepwise substrate modification until noninducibility (group B, n=250)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Group B (stepwise substrate modification)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Group A (elimination of triggers)
Number of subjects: 500
Study: 28629419

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 1219

Group type: COMPARATOR
Intervention: No beta-blockers
Number of subjects: 1219
Study: 26232172

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (40 mg/kg every 8 hours for up to 6 doses)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Normal saline placebo (every 8 hours for up to 6 doses)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 208

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 208
Study: 23515116

Group type: EXPERIMENTAL
Intervention: Family recommendations
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Perceived self-efficacy
Number of subjects: 250
Study: 21353271

Group type: EXPERIMENTAL
Intervention: Triple combination therapy of albendazole, ivermectin, and praziquantel
Number of subjects: 235

Group type: COMPARATOR
Intervention: Current NTD programme regimen (control)
Number of subjects: 235
Study: 18348383

Group type: EXPERIMENTAL
Intervention: Active drug (patch with extract of glycyrrhiza root)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 69

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 69
Study: 21429413

Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure (BIPAP) treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 15765952

Group type: EXPERIMENTAL
Intervention: Fiber posts and composite
Number of subjects: 219

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 219
Study: 12446158

Group type: EXPERIMENTAL
Intervention: Chronic low back pain group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study: 9839760

Group type: EXPERIMENTAL
Intervention: 5 mg donepezil for 28 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg donepezil for 21 days after 7 days of 5 mg donepezil
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both dosage regimens (5 mg and 10 mg donepezil)
Number of subjects: 16
Study: 8076659

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (delayed initiation beyond 24 hours and long-term maintenance treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate aspirin and thrombolytic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study: 2646383

Group type: EXPERIMENTAL
Intervention: Adenoidectomy (A)
Number of subjects: 147

Group type: COMPARATOR
Intervention: No pharyngeal surgery (NS)
Number of subjects: 147
Study: 29987456

Group type: EXPERIMENTAL
Intervention: Prednisolone and mizoribine with warfarin and dipyridamole (group 1)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Prednisolone and mizoribine without warfarin and dipyridamole (group 2)
Number of subjects: 71
Study: 28325124

Group type: EXPERIMENTAL
Intervention: Obstetric gel
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no obstetric gel)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Obstetric gel (among nulliparous women)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control (no obstetric gel, among nulliparous women)
Number of subjects: 180
Study: 26406148

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus (10 mg orally once daily)
Number of subjects: 821

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 821

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 821
Study: 23701411

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg single-dose (150 mL)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg multiple-dose (150 mL once daily for 7 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg regimen
Number of subjects: 100
Study: 21443305

Group type: EXPERIMENTAL
Intervention: Contingency management (CM)
Number of subjects: 393

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 393
Study: 19016090

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy for BN (duration not specified)
Number of subjects: 134
Study: 17135619

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT; 80% maximum heart rate)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT; 10 repetitions at 80% maximum strength, two sets and eight exercises)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No Training (Control)
Number of subjects: 45
Study: 14577344

Group type: EXPERIMENTAL
Intervention: DOT (Directly Observed Therapy) during admission
Number of subjects: 135

Group type: COMPARATOR
Intervention: Non-DOT (self-administered therapy) during admission
Number of subjects: 135
Study: 10918921

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8878167

Group type: EXPERIMENTAL
Intervention: Glucose infusion (50 mg/mL, 216 mL/h)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline infusion (9 mg/mL, 3 mL · kg‐1 · h‐1)
Number of subjects: 24
Study: 1613673

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (intravenous methylprednisolone 2 mg/kg body weight daily for 10 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (cotrimoxazole as standard treatment)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control
Number of subjects: 59
Study: 6439835

Group type: EXPERIMENTAL
Intervention: Regimen A (MFC + F): Induction therapy with mitomycin C, 5-fluorouracil, and cytosine arabinoside followed by intermittent oral administration of 5-fluorouracil for two years.
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Regimen B (MF'C + F'): Ftorafur administered on the same schedule as regimen A.
Number of subjects: 243

Group type: COMPARATOR
Intervention: Regimen C: Surgery alone (control).
Number of subjects: 243
Study: 29371384

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 14 days on/off
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 28 days on/off
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo 14 days on/off
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo 28 days on/off
Number of subjects: 351
Study: 26938489

Group type: EXPERIMENTAL
Intervention: Internet-Based Glucose Management System (IBGMS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 182
Study: 25033847

Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 24358226

Group type: EXPERIMENTAL
Intervention: In-group faces
Number of subjects: 0
Study: 20113674

Group type: EXPERIMENTAL
Intervention: Arthroscopic lavage (with or without debridement at the clinical discretion of the surgeon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-operative management with specialist reassessment
Number of subjects: 0
Study: 18468322

Group type: EXPERIMENTAL
Intervention: Prosthodontic treatments (specific interventions not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Denture hygiene and implants (commercially attractive topics)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 16631060

Group type: EXPERIMENTAL
Intervention: Perioperative sub‐Tenon's injection of triamcinolone (30 mg)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Perioperative sub‐Tenon's injection of triamcinolone (20 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Steroid drops (control group)
Number of subjects: 54
Study: 15446673

Group type: EXPERIMENTAL
Intervention: Weight-control intervention
Number of subjects: 45
Study: 11704023

Group type: EXPERIMENTAL
Intervention: 0.5% aqueous timolol (timolol solution)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 0.5% timolol suspension (timolol gellan)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 9065721

Group type: EXPERIMENTAL
Intervention: Rx 2 (high-dose carboplatin (HD-CBDCA) 500 mg/m2/day for 2 days and VP-16 100 mg/m2/day for 3 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rx 3 (ifosfamide 1.5 g/m2/day for 3 days followed by carboplatin (CBDCA) 400 mg/m2 on day 4)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rx 1 (high-dose cisplatin (HDP) 200 mg/m2 with concurrent sodium thiosulfate (STS) 9.9 g/m2 and etoposide (VP-16) 200 mg/m2/day for 3 days)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Rx 2 and Rx 3
Number of subjects: 46
Study: 8213512

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 20
Study: 3318260

Group type: EXPERIMENTAL
Intervention: P-hGH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: B-hGH
Number of subjects: 9

Group type: COMPARATOR
Intervention: im injection of hGH
Number of subjects: 9

Group type: COMPARATOR
Intervention: sc injection of hGH
Number of subjects: 9
Study: 31734701

Group type: EXPERIMENTAL
Intervention: Hybrid Comprehensive Telerehabilitation (HCTR) program (1 week in hospital and 8 weeks at home)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 850
Study: 28947165

Group type: EXPERIMENTAL
Intervention: ADL retraining during PTA (treatment group)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone (control group)
Number of subjects: 104
Study: 26704772

Group type: EXPERIMENTAL
Intervention: BRIPPED scan
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 104
Study: 25552236

Group type: EXPERIMENTAL
Intervention: Ultrapro mesh
Number of subjects: 950

Group type: COMPARATOR
Intervention: Prolene mesh
Number of subjects: 950

Group type: EXPERIMENTAL
Intervention: Severe preoperative pain
Number of subjects: 950
Study: 23093054

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1500 IU) plus fluoxetine (20 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Fluoxetine alone (20 mg)
Number of subjects: 42
Study: 20466680

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vardenafil
Number of subjects: 32
Study: 18181241

Group type: EXPERIMENTAL
Intervention: D-chlorpheniramine 6 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 16946391

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in UK journals
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs) in USA journals
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Systematic reviews in UK journals
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Systematic reviews in USA journals
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Comparison of RCTs between UK and USA journals
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Comparison of systematic reviews between UK and USA journals
Number of subjects: 1135
Study: 12749509

Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg QD given i.v. and then orally for 7 to 15 days
Number of subjects: 438

Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg to 1 g i.v. every 6 to 8 hours, followed by oral ciprofloxacin 750 mg every 12 hours for 7 to 15 days
Number of subjects: 438
Study: 10065749

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7478123

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole prophylaxis starting 1 day after transplantation for 4 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 28
Study: 2119524

Group type: EXPERIMENTAL
Intervention: Monoclate
Number of subjects: 0
Study: 7386234

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28777385

Group type: EXPERIMENTAL
Intervention: XLHA + CoQ10
Number of subjects: 40

Group type: COMPARATOR
Intervention: HA
Number of subjects: 40
Study: 26701971

Group type: EXPERIMENTAL
Intervention: Single-dose methotrexate (n = 46)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Two-dose methotrexate (n = 46)
Number of subjects: 92
Study: 24134194

Group type: EXPERIMENTAL
Intervention: NT-020 (n=52)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo (n=53)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: NT-020
Number of subjects: 105
Study: 23952894

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 37
Study: 20138809

Group type: EXPERIMENTAL
Intervention: 39 Gy in 13 fractions over 5 weeks
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: 41.6 Gy in 13 fractions over 5 weeks
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions over 3 weeks
Number of subjects: 2208

Group type: COMPARATOR
Intervention: 50 Gy in 25 fractions (control)
Number of subjects: 2208
Study: 18721224

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD) in patients aged 70 and older
Number of subjects: 1813

Group type: COMPARATOR
Intervention: Hemodialysis (HD) in younger cohorts (aged 55 to 69 and 18 to 54)
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: All age groups undergoing HD
Number of subjects: 1813
Study: 16629864

Group type: EXPERIMENTAL
Intervention: Solid meal (250 kcal) containing 13C-octanoate, n = 40
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Liquid meal (315 kcal) with 13C-acetate, n = 40
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy control group, n = 40
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Motor handicaps (rigour and action tremor)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Severity of motor impairment (UPDRS)
Number of subjects: 80
Study: 14563972

Group type: EXPERIMENTAL
Intervention: UK-279,276 (dose range, 10 to 120 mg)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: UK-279,276 in tissue plasminogen activator-treated subset
Number of subjects: 966

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 966
Study: 10573670

Group type: EXPERIMENTAL
Intervention: Ab-Flex
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ab-Roller
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard Crunch
Number of subjects: 26
Study: 8546341

Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day) plus Quinapril (10 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (age-matched)
Number of subjects: 21
Study: 2035513

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression from normal glucose tolerance to impaired glucose tolerance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression from normal glucose tolerance to non-insulin-dependent diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Progression from impaired glucose tolerance to non-insulin-dependent diabetes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall age-standardized incidence of non-insulin-dependent diabetes
Number of subjects: 0
Study: 6762829

Group type: EXPERIMENTAL
Intervention: Pre and postoperative gentamycin plus clindamycin or lincomycin
Number of subjects: 88

Group type: COMPARATOR
Intervention: Postoperative gentamycin plus clindamycin or lincomycin
Number of subjects: 88
Study: 3909759

Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release tablets, 20 mg twice daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30801500

Group type: EXPERIMENTAL
Intervention: Children with SPD
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Children with SPD (boys)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Children with TD
Number of subjects: 150
Study: 29385062

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (1000 mg capsules containing 180 mg eicosapentaenoic acid and 120 mg docosahexaenoic acid, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 26541738

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.3 mcg/kg/h for 24 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine infusion (3 mg/h for 24 hours)
Number of subjects: 60
Study: 24797222

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Oral hygiene instructions
Number of subjects: 154
Study: 23198510

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated wipes used thrice weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate-impregnated wipes
Number of subjects: 0
Study: 20184866

Group type: EXPERIMENTAL
Intervention: Alendronate therapy
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 601
Study: 18577886

Group type: EXPERIMENTAL
Intervention: 5 mg mosapride citrate
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: 50 mg itopride hydrochloride
Number of subjects: 613

Group type: COMPARATOR
Intervention: Vehicle (100 ml water) alone
Number of subjects: 613
Study: 15691343

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (CHX; Chlorhexamed forte, 0.2%)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (Meridol, 250 ppm; ASF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 7
Study: 12492904

Group type: EXPERIMENTAL
Intervention: Colgate Total (0.3% triclosan + 2% pvm/ma)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Signal Global (0.3% triclosan + 0.75% Zn)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Crest Complete (0.3% triclosan + 5% PPi)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Experimental dentifrice (0.3% triclosan + 2% pvm/ma + 0.75% Zn + 4% PPi)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control dentifrice (without anti‐plaque agents)
Number of subjects: 19
Study: 10048684

Group type: COMPARATOR
Intervention: Vitamin A supplements (400,000 IU); given at baseline, 4 months, and 8 months after discharge.
Number of subjects: 687
Study: 8579884

Group type: EXPERIMENTAL
Intervention: Webril patch
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hill Top patch
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Finn chamber
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Van der Bend chamber
Number of subjects: 6
Study: 2405789

Group type: EXPERIMENTAL
Intervention: Dipyridamole (5 mg/kg/day) for 12 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 53
Study: 6767959

Group type: EXPERIMENTAL
Intervention: Gentamicin once daily (120 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Gentamicin twice daily (40/80 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Gentamicin three times daily (40 mg)
Number of subjects: 165
Study: 30467342

Group type: EXPERIMENTAL
Intervention: Dexamethasone or hydrocortisone
Number of subjects: 0
Study: 30646395

Group type: EXPERIMENTAL
Intervention: PAD + CVD
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: PAD + CAD
Number of subjects: 13885

Group type: EXPERIMENTAL
Intervention: PAD + CAD + CVD
Number of subjects: 13885
Study: 26831124

Group type: EXPERIMENTAL
Intervention: enalapril-lercanidipine (EL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: enalapril-felodipine (EF)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: enalapril-lercanidipine (EL) uptitrated to 20 mg/d
Number of subjects: 36

Group type: COMPARATOR
Intervention: enalapril-felodipine (EF) uptitrated to 10 mg/d
Number of subjects: 36
Study: 24559212

Group type: EXPERIMENTAL
Intervention: Complex small group educational seminar on antibiotic prescribing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup of adult patients affected by odontogenic infections
Number of subjects: 0
Study: 22251408

Group type: EXPERIMENTAL
Intervention: Paricalcitol (mean initiation dose: 23 ± 7 μg/week)
Number of subjects: 40
Study: 19556926

Group type: COMPARATOR
Intervention: Oral Contraceptives (OC)
Number of subjects: 571

Group type: COMPARATOR
Intervention: Depot-medroxyprogesterone acetate (DMPA)
Number of subjects: 571
Study: 17236845

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) mechanical bowel preparation
Number of subjects: 670

Group type: COMPARATOR
Intervention: Sodium phosphate (SP) mechanical bowel preparation
Number of subjects: 670

Group type: COMPARATOR
Intervention: Sodium phosphate (SP) with ertapenem antibiotic prophylaxis
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) with cefotetan antibiotic prophylaxis
Number of subjects: 670
Study: 15059701

Group type: EXPERIMENTAL
Intervention: Valganciclovir therapy (900 mg daily)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Withdrawal of valganciclovir therapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Valganciclovir therapy
Number of subjects: 5
Study: 10689236

Group type: EXPERIMENTAL
Intervention: Oral ETEC B-subunit-inactivated whole cell vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0